Evotec has a long history of contributing to the oncology field through partners, achieving numerous oncology milestones including multiple PDCs, 14 clinical drugs and 1 marketed product.
Our dedicated oncology team assists pharmaceutical, biotech, not-for-profit and academic organisations in their drug discovery research activities offering a comprehensive panel of activities from target identification to pre-clinical candidate through a highly sophisticated and integrated drug discovery platform.
Evotec has established a leading technology platform enabling the discovery, development and clinical translation of new cancer therapies. Evotec’s expertise includes the evaluation of small molecular weight compounds, natural compounds, biologics and vaccines.
With a team of ~100 scientists dedicated to oncology, Evotec has a significant background in a broad range of scientific areas, including tumour microenvironment, immuno-oncology, signal transduction, cancer metabolism and epigenetics.